Table 4.
Study population characteristics of 33 included studies
|
Characteristics |
Included? |
Median (IQR)*, n |
||
| Yes | No | Unknown | ||
| Age† | – | – | 15 | 41 (37–49), n=18 |
| HIV | 18 | 7 | 8 | 23% (10–100), n=17 |
| Diabetes | 13 | 1 | 19 | 12% (5–21), n=11 |
| MDR | 8 | 7 | 18 | 1% (1–3), n=8 |
| Other drug resistance | 12 | 1 | 20 | 6% (4–12), n=10 |
| Extrapulmonary TB‡ | 22 | 4 | 7 | 11%(4–17), n=16 |
| Previous TB | 20 | 1 | 12 | 19% (9–30), n=17 |
| DOT | 14 | 0 | 19 | 100% (100–100), n=14 |
| Hospitalised patients | 13 | 1 | 19 | 100% (100–100), n=10 |
*Other than age (which is reported in years), this is the percentage of the population that has the characteristic among studies that include patients with the characteristic. For example, among the 18 studies that include persons with HIV, 17 report how many people had HIV and among those, the median percentage of the population with HIV is 23%.
†Based on the measure of central tendency reported in the study (mean: n=11; median: n=7).
‡Forms of extrapulmonary TB differ by study but included some of the following: miliary, meningeal, pleural, peritoneal, disseminated, blood/bone, abdominal.
DOT, directly observed therapy; MDR, multidrug resistance; TB, tuberculosis.